Using mHealth to Optimize Pharmacotherapy Regimens

Sponsor
New York State Psychiatric Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04248517
Collaborator
Northwell Health, Early Treatment Program at Lenox Hill (Other), The Institute for Family Health Center for Counseling at Walton (Other), New York State Psychiatric Institute, Washington Heights Community Service (Other), Bestself Behavioral Health, Inc. (Other)
23
4
2
25.7
5.8
0.2

Study Details

Study Description

Brief Summary

This project will use a smartphone technology to improve medication prescribing for individuals with FEP. We will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team members with clinically relevant and time-sensitive information that will inform and promote shared decision making (SDM) and personalized interventions. The result will be a time-sensitive, data-driven, collaborative process to optimize medication regimens in order to maximize benefits, minimize harms, and promote adherence.

Condition or Disease Intervention/Treatment Phase
  • Other: mHealth Intervention
N/A

Detailed Description

Comprehensive early treatment of individuals experiencing schizophrenia has the potential to alter the course of illness and improve long-term outcomes. Psychotropic medications are a critical component of early treatment strategies. First-episode psychosis (FEP) is a critical time to optimize prescribing but evidence suggests that prescribing for this population is suboptimal.

A contributing factor to these difficulties is thought to be the lack of accurate information about the effects of medications on symptoms, their side effects, as well as their behavioral, cognitive, and emotional correlates. At medication management appointments, prescribers typically rely on patients' recollection of how they were doing over periods of weeks. Such retrospective assessments are problematic as they are vulnerable to the influence of memory difficulties, cognitive biases including recency effects and frequency illusions, and reframing. Recent advances in smartphone technologies (mobile Health; mHealth) may help to overcome many of the limitations of retrospective assessments.

This pilot study will be a collaboration with OnTrackNY, an innovative coordinated specialty care (CSC) program for individuals aged 16-30 who are experiencing FEP. OnTrackNY originated as part of the NIMH Recovery After an Initial Schizophrenia Episode (RAISE) Implementation and Evaluatoin Study. The initial phase of this project will use input from stakeholders including patients, front-line providers, clinical leaders, and members of the research team to adapt and refine the mHealth intervention to improve feasibility and clinical utility. A pilot study at 3 OnTrackNY sites will then examine its feasibility and effectiveness by comparing the management and outcomes of 60 patients randomly assigned to the mHealth application or usual care.

Study Design

Study Type:
Interventional
Actual Enrollment :
23 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective cohort with comparison groupProspective cohort with comparison group
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Using mHealth to Optimize Pharmacotherapy Regimens
Actual Study Start Date :
Oct 9, 2020
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: mHealth intervention group

participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.

Other: mHealth Intervention
Participants will download the app onto their smartphone and complete ecological momentary assessements

No Intervention: Treatment as Usual group

participants will undergo their routine treatment.

Outcome Measures

Primary Outcome Measures

  1. change of Treatment Satisfaction Questionnaire for Medication (TQSM) from baseline to 6 months [baseline to 6 months]

    The TSQM assesses client satisfaction with medication. It comprises 14 items across four domains focusing on effectiveness (3 items), side effects (5 items), convenience (3 items), and global satisfaction (3 items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied).The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring. If an item score is missing and half of the items in the domain are complete, domain scores may be imputed from the person-specific mean score of completed items.

  2. change of Client Satisfaction Questionnaire (CSQ-8) from baseline to 6 months [baseline to 6 months]

    8-item easily scored and administered measurement that is designed to measure client satisfaction with services. The overall score is produced by summing all item responses. Scores range from 8 to 32, with higher values indicating higher satisfaction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female OnTrackNY participants, ages 16 to 30, of any race/ethnicity

  • Able and willing to give informed consent and participate in the intervention

  • Participating in OnTrackNY for less than 1 year because this group may be more in need of medication adjustments and will be less likely to graduate from the program before 6 months of participation.

Exclusion Criteria:
  • Suicidal at baseline with C-SSRS score 4 or 5.

  • PANSS baseline score of 5 (moderately severe) or greater on the Conceptual Disorganization item (P2)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bestself Behavioral Health, Inc. Buffalo New York United States 14202
2 Washington Heights Community Service New York New York United States 10032
3 Lenox Hill Hospital New York New York United States 10065
4 Institute for Family Health New York New York United States 10453

Sponsors and Collaborators

  • New York State Psychiatric Institute
  • Northwell Health, Early Treatment Program at Lenox Hill
  • The Institute for Family Health Center for Counseling at Walton
  • New York State Psychiatric Institute, Washington Heights Community Service
  • Bestself Behavioral Health, Inc.

Investigators

  • Principal Investigator: Scott Stroup, MD, MPH, New York State Psychiatric Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Scott Stroup, Professor of Psychiatry, New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT04248517
Other Study ID Numbers:
  • 7900
First Posted:
Jan 30, 2020
Last Update Posted:
Aug 8, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Scott Stroup, Professor of Psychiatry, New York State Psychiatric Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2022